Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN known ✓ | Q96SW2 | 1/20 | 0.42 |
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.32 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.32 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.30 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.30 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL725678 | 0.97 | — | — | |
| Succinic Acid SCHEMBL7644469 | 0.85 | PHF8 (0.41) | CRBNLMNA | |
| Glycine SCHEMBL2192780 | 0.85 | GLRA1 (0.40) | CRBN | |
| Metformin SCHEMBL3688836 | 0.79 | HTT (0.32) | CRBNHTT | |
| Metformin SCHEMBL4421557 | 0.79 | HTT (0.39) | HTTLMNADPP4ADRA1A | |
| Metformin SCHEMBL18953625 | 0.79 | HTT (0.39) | HTTLMNADPP4ADRA1A | |
| Metformin SCHEMBL19583451 | 0.79 | HTT (0.39) | HTTLMNADPP4ADRA1A | |
| Metformin SCHEMBL15268394 | 0.79 | HTT (0.39) | HTTLMNADPP4ADRA1A | |
| Metformin SCHEMBL433864 | 0.79 | HTT (0.39) | HTTLMNADPP4ADRA1A | |
| Metformin SCHEMBL22977 | 0.79 | HTT (0.39) | HTTLMNADPP4ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 377 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009031044-A2 | AMPK DEFICIENT ANIMALS, SCREENING METHODS, AND RELATED THERAPEUTICS AND DIAGNOSTICS | GENEXEL-SEIN, INC. (US) | 2009-03-12 | — | — | WO | claimed |
| US-20090042810-A1 | AMPK Deficient Animals, Screening Methods, And Related Therapeutics And Diagnostics | GENEXEL-SEIN, INC. | 2009-02-12 | — | — | US | claimed |
| US-20250387389-A1 | METHODS OF TREATING DISEASE WITH LEVOKETOCONAZOLE | XERIS PHARMACEUTICALS, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-12377096-B2 | Methods of treating disease with levoketoconazole | XERIS PHARMACEUTICALS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-20250171497-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LIMITED (IE) | 2025-05-29 | — | — | US | disclosed |
| US-20250049881-A1 | FORMULATIONS OF GUANYLATE CYCLSE C AGONISTS AND METHODS OF USE | JPMORGAN CHASE BANK, N.A. | 2025-02-13 | — | — | US | disclosed |
| US-12146003-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2024-11-19 | — | — | US | disclosed |
| EP-4424697-A2 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | Bausch Health Ireland Limited (IE) | 2024-09-04 | — | — | EP | disclosed |
| US-20240287137-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2024-08-29 | — | — | US | disclosed |
| US-11980214-B2 | Dietary fiber compositions with psyllium and methods of use | INOVOBIOLOGIC INC. (CA) | 2024-05-14 | — | — | US | disclosed |
| US-20240148724-A1 | METHODS OF TREATING DISEASE WITH LEVOKETOCONAZOLE | STRONGBRIDGE DUBLIN LIMITED (US) | 2024-05-09 | — | — | US | disclosed |
| US-20010046515-A1 | A core formulation comprising, a first layer of pioglitazone hydrochloride or a salt as an active ingrediant, a core, atleast a portion of which is enclose by first layer comprising a biguanide, a modulating silicate polymer | KOS LIFE SCIENCES, INC. | 2001-11-29 | — | — | US | disclosed |
| WO-2001082867-A2 | A CORE FORMULATION | AEROPHARM TECHNOLOGY, INC. (US) | 2001-11-08 | — | — | WO | disclosed |
| US-20010036478-A1 | Core formulation | KOS LIFE SCIENCES, INC. | 2001-11-01 | — | — | US | disclosed |
| US-20010034374-A1 | Core formulation | KOS LIFE SCIENCES, INC. | 2001-10-25 | — | — | US | disclosed |
| US-6296874-B1 | Core formulation comprising troglitazone and abiguanide | AEROPHARM TECHNOLOGY INCORPORATED | 2001-10-02 | — | — | US | disclosed |
| US-6117451-A | DIRECT TABLETING, FREE-FLOWING PARTICULATE METFORMIN HCL FORMULATION IN THE FORM OF A TABLETING POWDER, CAPABLE OF BEING DIRECTLY COMPRESSED INTO A TABLET WITH HARDNESS, RAPID DISINTEGRATION TIME AND ACCEPTABLE DISSOLUTION PATTERN | PHARMALOGIX, INC. (US) | 2000-09-12 | — | — | US | disclosed |
| US-6011049-A | Combinations for diabetes | WARNER-LAMBERT COMPANY (US) | 2000-01-04 | — | — | US | disclosed |
| US-5254593-A | Compositions containing biguanides and derivatives thereof as inhibitors of nonenzymatic cross-linking | THE ROCKEFELLER UNIVERSITY (US) | 1993-10-19 | — | — | US | disclosed |
| WO-1992007560-A1 | BIGUANIDES AND DERIVATIVES THEREOF AS INHIBITORS OF ADVANCED GLYCOSYLATION OF A TARGET PROTEIN | THE ROCKEFELLER UNIVERSITY (US) | 1992-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12146003-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | CRBN 2909/4885DPP4 1322/4885ADRA1A 165/4885 |
| US-20250387389-A1 | METHODS OF TREATING DISEASE WITH LEVOKETOCONAZOLE | SLC5A2, SLC10A1, SLC6A11 | CRBN 3216/4885DPP4 735/4885ADRA1A 1829/4885 |
| US-20250171497-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | CRBN 2909/4885DPP4 1322/4885ADRA1A 165/4885 |
| US-20240287137-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | CRBN 2909/4885DPP4 1322/4885ADRA1A 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.